RFO
CLB icon

RiverGlades Family Offices’s Core Laboratories CLB Stock Holding History

RiverGlades Family Offices’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,600
Closed -$209K – 80
2022
Q1 		$209K Buy
+6,600
New +$185K 0.16% 78

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RiverGlades Family Offices's CLB Position: Q2 2022 in Review

RiverGlades Family Offices sold out of Core Laboratories (CLB) in Q2 2022, closing a stake of 6,600 shares — an estimated $209K sold.

RiverGlades Family Offices first reported a position in CLB in Q1 2022 and held it in 1 quarter. The position peaked at $209K in Q1 2022. 176 funds tracked by Wall St. Rank hold CLB as of Q2 2022.

  • RiverGlades Family Offices reported no remaining Core Laboratories position as of Q2 2022 after selling out during the quarter.
  • RiverGlades Family Offices sold 6,600 Core Laboratories shares in Q2 2022, an estimated $209K.
  • RiverGlades Family Offices first reported a position in Core Laboratories in Q1 2022 and held it in 1 quarter.
  • RiverGlades Family Offices's Core Laboratories position peaked at $209K in Q1 2022.
  • 176 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2022.

Based on RiverGlades Family Offices's 13F filing for Q2 2022, filed 12 Aug 2022.